Research shows SGLT2 inhibitors can alleviate the damage of MI in diabetic and non-diabetic hearts (144–146), reduce MIRI by inhibiting cardiomyocyte autophagy and protecting mitochondrial function, and reduce cardiovascular mortality and heart failure (HF) rehospitalization rate of patients after myocardial ischemia-reperfusion by targeting multiple pathways (26, 146–148). Here, SLC5A2 is linked to heart failure.